Artes Medical's ArteFill Selected as Finalist for San Diego's Connect "Most Innovative New Product" Award.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company whose product ArteFill[R] is the first and only FDA-approved non-resorbable injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. filler for the correction of nasolabial fold or "smile line" wrinkles wrinkles See bells and whistles. , today announced its flagship product A primary product of a company, which is typically why the company was founded and/or what made it well known. For example, MS-DOS, Windows and the Microsoft Office suite have been flagship products of Microsoft. CorelDRAW is a flagship product of Corel Corporation. , ArteFill has been selected as a finalist in the 2007 CONNECT Most Innovative New Products "MIP MIP See: Monthly income preferred security " Awards. ArteFill is one of three finalists in the Medical Products category. This year, 93 entries in six categories were received overall. Artes Medical presented the merits of ArteFill to a panel of distinguished judges on November 9, 2007. Winners will be announced at the MIP Awards Ceremony on December 14, 2007 in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . "We are proud and honored to be one of the finalists in CONNECT's prestigious MIP awards program. I'd like to congratulate all of our employees for their commitment that has allowed us to successfully develop and commercialize ArteFill, a truly innovative and differentiated product," said Diane S. Goostree, President and Chief Executive Officer. "We are excited to offer our outstanding medical technology to physicians and patients, as we accelerate the commercial phase and market launch of ArteFill, the first and only FDA-approved non-resorbable injectable dermal filler for the correction of facial wrinkles known as smile lines." The CONNECT MIP Awards program has served as a benchmark for predicting the region's most successful emerging technologies. From early stage biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. ; to the first products generated by the region's telecommunications boom, MIP has been an indicator of the industries and technologies that have stimulated the San Diego economy. CONNECT is a non-profit organization A non-profit organization (abbreviated "NPO", also "non-profit" or "not-for-profit") is a legally constituted organization whose primary objective is to support or to actively engage in activities of public or private interest without any commercial or monetary profit purposes. dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Since 1985, CONNECT has assisted in the formation and development of over 1,000 companies and is widely regarded as the nation's most successful regional program linking inventors and entrepreneurs with the resources they need for success. About ArteFill[R] ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments. ArteFill was approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in October 2006 based on data from the Company's 12 month controlled, randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the six month evaluation, which was the primary efficacy evaluation period Evaluation period The time interval over which funds assess a money manager's performance. for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment pretreatment, n the protocols required before beginning therapy, usually of a diagnostic nature; before treatment. pretreatment estimate, n See predetermination. status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction. An ArteFill Skin Test is required before initial treatment. The most common adverse events associated with ArteFill treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or redness and increased sensitivity at the injection site. ArteFill is a proprietary formulation comprised of polymethylmethacrylate, or PMMA PMMA polymethyl methacrylate. , microspheres and bovine collagen, and is the only PMMA-based injectable product that has been approved by the FDA for the treatment of facial wrinkles. Artes Medical is the sole manufacturer of ArteFill, which is only available in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. through Artes Medical, and Artes Medical has not entered into distribution or licensing arrangements with any third party for the distribution or sale of ArteFill, or any other PMMA-based dermal filler, outside the United States. About Artes Medical, Inc. Artes Medical is a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for the dermatology and plastic surgery markets. The Company's initial product, ArteFill[R], is being marketed to men and women as a treatment option for the correction of nasolabial folds. Additional information about Artes Medical and ArteFill is available at www.artesmedical.com and www.artefill.com. Forward-Looking Statements This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, which include the Company's history of net losses, its reliance on its sole FDA-approved product, ArteFill, its limited experience in commercializing ArteFill, its ability to receive FDA approval to claim that the aesthetic benefits of ArteFill extend beyond six months and delays in the market acceptance of ArteFill, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. A more extensive set of risks and uncertainties is set forth in the Company's SEC filings available at www.sec.gov. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future. Artes Medical[R] and ArteFill[R] are registered trademarks of Artes Medical, Inc. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion